Subclinical disease activity in MS ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌    Intervening before clinical symptoms occur is important to slowing cognitive decline in multiple sclerosis (MS)1 Evidence suggests that some level of cognitive impairment is present in a significant proportion of people before clinical symptoms of MS occur1 Cognitive deficits may precede onset of MS by as much as 1.2 years2   Some studies have shown that approximately 20%–30% of people with MS have already experienced cognitive changes at the time of their first clinical event2   Learn more about early cognitive decline   Drs. Vollmer and Foley discuss the significance of early subclinical disease activity and the importance of intervening early   Watch the discussion: Early detection and intervention in MS   References: 1. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Mult Scler Relat Disord. 2016;9(suppl 1):S5-S48. 2. MS Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A consensus paper by the Multiple Sclerosis Coalition. ht‍tp:/‍/ww‍w.national‍mssociety.o‍rg/get‍media/5ca‍284d3-fc‍7c-4ba5-b‍005-ab53‍7d495c3c/DMT_Consens‍us_MS_Coaliti‍on_color. Updated M‍arch 20‍17. Accessed Ju‍ly 1‍8, 20‍18. You have received this email because you agreed to receive communications from Biogen. If you prefer not to receive further messages from this sender, please click here to unsubscribe and confirm your request.   © 2018 Biogen. All rights reserved. 08/18 FCH-US-4221 225 Binney Street Cambridge, MA 02142 800-456-2255